8. Tom SteyerTop Pick: Revolution Medicines, Inc. (NASDAQ:RVMD)
Tom Steyer ranks among the list of the richest hedge fund managers in the world. Revolution Medicines, Inc. (NASDAQ:RVMD) is Tom Steyer’s largest holding, accounting for 5.26% of the billionaire’s total portfolio.
In response to the company’s first-quarter 2026 results, Needham reduced its price target for Revolution Medicines, Inc. (NASDAQ:RVMD) to $183 from $186 on May 7, keeping a Buy rating on the stock.
The company’s loss per share came in at $2.29, falling short of the consensus forecast of a loss of $1.64. The shortfall was caused by higher-than-expected marketing, general, and administrative costs of $46.3 million, as well as R&D costs of $67.4 million.
Meanwhile, the company hiked its full-year 2026 stock-based expense projection to around $260 million and $280 million, representing an increase of about $80 million.
Revolution Medicines, Inc. (NASDAQ:RVMD) also stated that enrollment in its RASolute 301 study, which is investigating Dara in second-line non-small cell lung cancer, has increased from 420 to 590 patients, thereby increasing the statistical impact on overall survival, a dual primary objective. According to the company, the adjustment has no bearing on the study’s timeline, which is projected to be completed in large part by 2026.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.
7. Andreas Halvorsen
Top Pick: Microsoft Corporation (NASDAQ:MSFT)
Andreas Halvorsen ranks among the richest hedge fund managers in the world. Accounting for a 4.13% share ($1.55 billion) in the billionaire’s portfolio, Microsoft Corporation (NASDAQ:MSFT) ranks as Andreas Halvorsen’s top stock pick.
The UK’s Competition and Markets Authority (CMA) has initiated a probe into Microsoft Corporation (NASDAQ:MSFT)’s commercial software infrastructure, the regulatory agency announced on May 14. The investigation attempts to assess whether product bundling, compatibility constraints, and embedded AI tools jeopardize fair competition.
The agency has set aside nine months for the probe, which will gather information from Microsoft Corporation (NASDAQ:MSFT), its clients, and competitors. The CMA previously approved Microsoft last year in a probe for its collaboration with OpenAI, which began in 2023.
However, the tech giant wasn’t successful in another case involving competition in the cloud market. While some FAANG competitors were also investigated, Microsoft Corporation (NASDAQ:MSFT) received the weight of the ultimate ruling, which called it out for monopolistic software licensing tactics.
Microsoft Corporation (NASDAQ:MSFT) altered its UK rules back in March to meet CMA concerns, lowering Azure outflow fees and getting rid of limits on switching and multicloud compatibility.
Microsoft Corporation (NASDAQ:MSFT) develops and sells a wide range of software, cloud services, devices, and business solutions, serving both individual users and enterprise customers worldwide.
